11/28
07:12 am
tak
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
Low
Report
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
11/25
01:57 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
01:21 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
01:30 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/8
07:05 pm
tak
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]
11/7
11:00 am
tak
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Low
Report
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
11/6
08:22 am
tak
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase [Yahoo! Finance]
Low
Report
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase [Yahoo! Finance]
11/3
07:00 am
tak
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Low
Report
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
11/1
08:05 pm
tak
Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss [Yahoo! Finance]
10/30
10:48 am
tak
Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence [Yahoo! Finance]
Neutral
Report
Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence [Yahoo! Finance]
10/30
03:04 am
tak
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Medium
Report
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
10/27
08:35 am
tak
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
Low
Report
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
10/22
05:55 pm
tak
Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight [Yahoo! Finance]
Low
Report
Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight [Yahoo! Finance]
10/21
08:32 pm
tak
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors [Yahoo! Finance]
Low
Report
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors [Yahoo! Finance]
10/21
08:25 pm
tak
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Low
Report
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
10/19
10:26 am
tak
Does Takeda Offer Value After Latest FDA Approval and Share Price Dip in 2025? [Yahoo! Finance]
Low
Report
Does Takeda Offer Value After Latest FDA Approval and Share Price Dip in 2025? [Yahoo! Finance]
10/14
12:17 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
10/14
05:12 am
tak
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership [Yahoo! Finance]
Low
Report
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership [Yahoo! Finance]
10/14
05:08 am
tak
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership [Yahoo! Finance]
Low
Report
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership [Yahoo! Finance]
10/9
05:33 pm
tak
Takeda Pharmaceutical (TSE:4502): Is the Market Missing Its True Valuation Potential? [Yahoo! Finance]
Medium
Report
Takeda Pharmaceutical (TSE:4502): Is the Market Missing Its True Valuation Potential? [Yahoo! Finance]
10/3
09:03 am
tak
How Investors May Respond To Takeda Pharmaceutical (TSE:4502) Exiting Cell Therapy to Refocus R&D Priorities [Yahoo! Finance]
Low
Report
How Investors May Respond To Takeda Pharmaceutical (TSE:4502) Exiting Cell Therapy to Refocus R&D Priorities [Yahoo! Finance]
10/2
04:26 am
tak
Mucopolysaccharidosis Market Analysis and Forecast Report, 2025-2035: Enzyme Replacement Therapies Lead While Gene Therapy Emerges as Next Frontier [Yahoo! Finance]
Medium
Report
Mucopolysaccharidosis Market Analysis and Forecast Report, 2025-2035: Enzyme Replacement Therapies Lead While Gene Therapy Emerges as Next Frontier [Yahoo! Finance]
10/1
08:30 am
tak
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis [Yahoo! Finance]
Low
Report
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis [Yahoo! Finance]
9/26
08:55 am
tak
Trump's 100% Drug Tariffs Sparks Selloff in Global Pharma Markets [Yahoo! Finance]
Low
Report
Trump's 100% Drug Tariffs Sparks Selloff in Global Pharma Markets [Yahoo! Finance]
9/24
12:42 pm
tak
Vitamin Angels and Takeda Unite to Tackle the Climate and Health Crisis in Indonesia [Yahoo! Finance]
Low
Report
Vitamin Angels and Takeda Unite to Tackle the Climate and Health Crisis in Indonesia [Yahoo! Finance]